CVRx (CVRX) and The Competition Head-To-Head Review

CVRx (NASDAQ:CVRX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare CVRx to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Volatility & Risk

CVRx has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, CVRx’s rivals have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.

Insider and Institutional Ownership

75.3% of CVRx shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 16.6% of CVRx shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares CVRx and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CVRx -88.28% -208.45% -55.42%
CVRx Competitors -270.28% -155.47% -22.38%

Analyst Ratings

This is a breakdown of recent recommendations for CVRx and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CVRx 1 5 1 0 2.00
CVRx Competitors 4311 10599 18393 838 2.46

CVRx currently has a consensus price target of $2.70, indicating a potential upside of 340.46%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.19%. Given CVRx’s higher possible upside, equities research analysts plainly believe CVRx is more favorable than its rivals.

Earnings & Valuation

This table compares CVRx and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CVRx $60.33 million -$53.31 million -0.30
CVRx Competitors $1.89 billion $135.83 million 5.73

CVRx’s rivals have higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

CVRx rivals beat CVRx on 9 of the 13 factors compared.

CVRx Company Profile

(Get Free Report)

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.